Bevacizumab is one of the rare drugs that could improve high-grade glioma outcome after failure of chemoradiotherapy.However,to date,there is no biomarker predictive for efficacy of bevacizumab therapy in terms of sur...Bevacizumab is one of the rare drugs that could improve high-grade glioma outcome after failure of chemoradiotherapy.However,to date,there is no biomarker predictive for efficacy of bevacizumab therapy in terms of survival improvement for patients with high-展开更多
文摘Bevacizumab is one of the rare drugs that could improve high-grade glioma outcome after failure of chemoradiotherapy.However,to date,there is no biomarker predictive for efficacy of bevacizumab therapy in terms of survival improvement for patients with high-
